The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 13, 2025

Filed:

May. 31, 2018
Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Barbra Johnson Sasu, San Francisco, CA (US);

Danielle Elizabeth Dettling, San Francisco, CA (US);

Cesar Adolfo Sommer, San Mateo, CA (US);

Yik Andy Yeung, South San Francisco, CA (US);

Moustafa Marc Hamze, Nogent-sur-Marne, FR;

Assignee:

PFIZER INC., New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464462 (2023.05); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/7151 (2013.01); C07K 16/2863 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).


Find Patent Forward Citations

Loading…